Allarity regains Nasdaq minimum bid price compliance after 20-day period

Allarity Therapeutics, Inc.

Received Nasdaq notice on Oct 9, 2024 confirming compliance with Listing Rule 5550(a)(2).
Stock closing bid price was $1.00 or greater for 20 consecutive days from Sept 11 to Oct 9, 2024.
Non-compliance was first notified on June 18, 2024; this matter is now closed.
CEO Thomas Jensen stated focus remains on stenoparib Phase 2 trial in advanced ovarian cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.